The detection of the Janus kinase 2 (JAK2) mutation V617F has become fundamental in the differential diagnosis of myeloproliferative syndromes (MPS) . While this mutation is common in bcr/abl translocation-negative (bcr/abl À ) MPS, that is, in polycythemia vera (490% of cases), 1 essential thrombocythemia and chronic idiopathic myelofibrosis (50-70% of cases each), 1 and occurs in B70% of cases of 'refractory anemia with ringed sideroblasts and thrombocytosis', 2, 3 it is consistently absent in chronic myelogenous leukemia 4 and a rare exception in acute myeloid leukemias, chronic myelomonocytic leukemias and myelodysplastic syndromes. 5 In spite of numerous investigations addressing the JAK2 genotype in MPS, no study has yet compared the different biological (RNA vs DNA) and technically available materials (native bone marrow/blood aspirates and bone marrow trephines vs 'historical' air-dried smears and paraffin-embedded trephines) in relation to the sensitivity of detecting the V617F mutation by PCR and sequencing. The proper choice among the Table 3 Biologic markers of bone remodeling in BP3 and BP1 patients respectively at the inclusion and at the end of the protocol Letters to the Editor various sources of DNA or RNA might become even more relevant with the advent of specific JAK2 inhibitors and the requirement for retrospective analyses on archival material. To define the optimal approach for the identification of the JAK2 V617F mutation in MPS, we compared from identical patients (n ¼ 44) (a) RNA and DNA from native bone marrow aspirates and heparinized peripheral blood samples, (b) RNA and DNA from air-dried, unfixed bone marrow and peripheral blood smears and (c) DNA from formalin-fixed, paraffinembedded bone marrow trephines and from air-dried bone marrow and blood smears. The 'historic' samples were 3 months to 6 years old. Patients' clinical data are given in Table 1 .
DNA and RNA were extracted as described previously. 6 For PCR/RT-PCR amplification of the JAK2 gene locus around nucleotide 1889 (corresponding to amino acid 617), the following oligonucleotide primers were used: for DNA (exon 12) (JAK2-UP 5 0 -TGAAGCAGCAAGTATGATGAGC-3 0 ; JAK2-LP1 5 0 -GTTTACACTGACACCTAGCTG-3 0 ); for RNA/cDNA (exons 12 and 13) (JAK2-UP 5 0 -TGAAGCAGCAAGTATGATGA GC-3 0 ; JAK2-LP2 5 0 -TTTCCTTGTCTTCCTGTCTTCTT-3 0 ). Purified PCR products (QiaQuick, Qiagen, Heidelberg, Germany) were sequenced on an ABI 3100 avant capillary sequencer (ABI, Heidelberg, Germany) using oligonucleotide primers as described above. Bcr/abl-negative MPS were classified according to World Health Organization (WHO)-based clinical, hematological, histopathological and genetic criteria (including bcr/abl RT-PCR, 6 Table 1 ). In a first step, we investigated RNA and DNA extracted from native bone marrow aspirates and peripheral blood samples as the presumed gold standard for the detection of JAK2 mutations. Indeed, the V617F gene locus was amplifiable from all extracted DNAs/RNAs of all patients investigated (n ¼ 44) (Table 1 ) and sequencing yielded completely overlapping results: 29 bcr/abl -MPS patients were V617F positive (Figure 1 ), while nine other bcr/abl -MPS patients and six controls were V617F negative.
We then tested 44 archival air-dried bone marrow and peripheral blood smears from the corresponding patients by extracting DNA/RNA from each which was the half of the same smear. The JAK2 V617F gene locus was amplifiable from all 44 DNAs (100%) but from only 23 of 44 RNA extracts (55%, Po0.0001). In DNA samples, the JAK2 mutation was detected again in 29 bcr/abl À MPS patients while nine other bcr/abl À MPS patients and controls were negative (Table 1) . Considering the 23 patients in whom amplification of the JAK2 gene locus was achieved in both DNA and RNA extracts as a separate group, there was a complete overlap between the frequencies of V617F-positive (n ¼ 15) and wild-type cases (n ¼ 8) ( Table 1) . Next we analyzed DNA extracted from formalin-fixed, paraffin-embedded bone marrow trephines and compared it with that from air-dried bone marrow smears and peripheral blood smears of the same age and from the same patients (n ¼ 44). In all samples, the JAK2 V617F gene locus could be amplified, and sequencing demonstrated again the V617F mutation in the same subset of 29 bcr/abl À MPS patients irrespective of the source of DNA (trephine, bone marrow or blood). No mutation was detected in any sample of the nine remaining bcr/abl À MPS patients and the controls (n ¼ 6). To test the sensitivity of the PCR-based detection of the JAK2 gene locus, we finally diluted 1 ml each from peripheral blood samples of JAK2 V617F mutation positive MPS patients (n ¼ 8) (median leukocyte count 8.5 Â 10 6 /ml, dilution steps 10 À1 -10
À5
) and extracted DNA/RNA with subsequent PCR/RT-PCR amplification of the JAK2 gene locus. As shown in Figure 2 , the RNA sample achieved a sufficient amplification at a dilution of 10 À4 , corresponding to 850 cells, whereas in the DNA-derived sample, the JAK2 gene locus could be amplified at a 10 À3 dilution, corresponding to 8500 cells. Moreover, when a specific amplificate was generated, the JAK2 mutation V617F was detected irrespective of dilution by subsequent sequencing analysis with an identical ratio of mutation/wild-type genome in all corresponding serial dilutions.
In summary, we show here that the JAK2 mutation V617F can be identified with the same high specificity in both DNA and RNA when native bone marrow aspirates or fresh peripheral blood samples from patients with de novo MPS are provided for amplification and sequencing of the JAK2 locus. Concerning the sensitivity of this technique, RT-PCR is about 10 times more sensitive that PCR. Therefore, RNA derived from fresh peripheral blood/bone marrow specimens appears to be the ideal starting material in conditions with a minor or diminished tumor cell load such as detection of minimal residual disease after chemotherapy/bone marrow transplantation. 7 By contrast, DNA is the preferred starting material for JAK2 mutation analysis when 'historic' material is available, be it air-dried blood or bone marrow smears or formalin-fixed, paraffinembedded bone marrow trephines. Since recently, a DNAbased quantitative PCR technique for the detection of the JAK2 mutation V617F was developed, 8 this archival material/DNA might be also appropriate for the quantification of the JAK2 mutational status. This will become even more important, when in the upcoming era of JAK2 inhibitors retrospective analyses on Table 1 Clinical data and JAK2 V617F mutational status of all patients (n ¼ 38) and controls (n ¼ 6) investigated Detection of JAK2 mutation V617F in DNA and RNA samples of bone marrow aspirates (BMA) and peripheral blood samples (PBS). (a) a complete lack of the wild-type cytidine (blue curve) with a complete switch to adenosine (green curve) at JAK2 nt.1889 (arrows) corresponding to JAK2 mutation V617F was detected in both DNA and RNA probes, indicating a homozygous JAK2V617F mutation status. In other cases (two representative cases shown in (b and c), variable ratios of wild-type (cytidine, blue curve) and mutated (adenosine, green curve) JAK2 nt.1889 with predominance either in DNA (b) or RNA samples (c) were detected, representing heterozygously mutated cases. , corresponding to approximately 8500 cells, whereas in RNA derived cDNA samples, a specific amplification was achieved at the even lower concentration of 1 Â 10 À4 (equivalent to 850 cells). PCR products of different dilution samples were purified and sequenced without any qualitative/quantitative change of the JAK2 mutational status.
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